squalamine manufacturers
- squalamine
-
- $10.00 / 1ASSAYS
-
2026-03-01
- CAS:148717-90-2
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- Squalamine
-
- $15.00 / 1KG
-
2021-07-13
- CAS:148717-90-2
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Squalamine
-
- $15.00 / 1KG
-
2021-07-10
- CAS:148717-90-2
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | squalamine Basic information |
| Product Name: | squalamine | | Synonyms: | (3β，5α，7α)-3-[[3-((4-Aminobutyl)amino)propyl]amino]cholestane-7，24-diol-24-hydrogen sulfate;MSI 1256;Squalamine, >98%;Cholestane-7,24-diol, 3-[[3-[(4-aminobutyl)amino]propyl]amino]-, 24-(hydrogen sulfate), (3β,5α,7α,24R)-;Cholestane-7,24-diol,3-[[3-[(4-aminobutyl)amino]propyl]amino]-, 24-(hydrogen sulfate), (3b,5a,7a,24R)- | | CAS: | 148717-90-2 | | MF: | C34H65N3O5S | | MW: | 627.96 | | EINECS: | 202-303-5 | | Product Categories: | | | Mol File: | 148717-90-2.mol |  |
| | squalamine Chemical Properties |
| density | 1.13±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (159.25 mM) | | form | Solid | | pka | -3.49±0.18(Predicted) | | color | Light yellow to yellow |
| | squalamine Usage And Synthesis |
| Uses | Squalamine is an aminosterol broad-spectrum antibacterial drug present in shark tissue. | | Definition | ChEBI: Squalamine is a bile acid. | | Biological Activity | Squalamine (MSI-1256) is a compound with broad-spectrum antiviral activity. | | Synthesis | Squalamine is isolated from the stomach of spiny horn shark and sea green dog shark. | | in vivo | Squalamine (2 mg/kg; Intraperitoneal injection; 28 days) inhibits tumor growth in xenografted mice with breast cancer[2].
Squalamine (20 mg; Single application; 0-3 days) has a decolonizing effect on S. aureus on the skin in a mouse model[3].
Squalamine (20-120 mg/kg; Oral gavage; 5 days) restores the function of the mesenteric nervous system in PD mouse models[4]. | Animal Model: | Female athymic mice aged 6 weeks old bearing breast tumor xenografts[2] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 28 days | | Result: | Significantly retarded the growth of tumors, but the combination with Trastuzumab (HY-P9907) was more effective.
Suppressed MCF-7/HER-2 breast xenograft-associated angiogenesis.
|
| Animal Model: | 10 μL S. aureus suspension(108 cfu/mL) was applied to the female BALB/c mice skin[3] | | Dosage: | 20 mg | | Administration: | Single application; 3 days | | Result: | Reduced S. aureus viable cells by up to 4 log after two days compared with the control.
|
| Animal Model: | PD mice models ( hSNCAA53T mice and PrP-A53T human α-syn overexpressing transgenic mice)[4] | | Dosage: | 20, 40, 80, or 120 mg/kg | | Administration: | Oral gavage (i.g.); 5 days | | Result: | Effectively restored disordered colonic motility in PD mice models.
Increased colonic transit in PrP-A53T mice.
Reduced myenteric intrinsic primary afferent neuron excitability in hSNCAA53T mice.
|
|
| | squalamine Preparation Products And Raw materials |
|